A long and winding road to understand latent autoimmune diabetes in adults

• Published in: Chinese medical journal Vol. 134; no. 1; pp. 1 - 4
• Main Authors: Luo, Shuo-Ming, Liu, Bing-Wen, Yin, Wen-Feng, Li, Xia, Zhou, Zhi-Guang
• Format: Journal Article
• Language: English
• Published: China Lippincott Williams & Wilkins Ovid Technologies 05.01.2021; Lippincott Williams & Wilkins; Wolters Kluwer
• Subjects: Adult; Adults; Age; Antigens; Body mass index; Classification; Diabetes; Diabetes Mellitus, Type 1 - diagnosis; Diabetes Mellitus, Type 1 - therapy; Diabetes Mellitus, Type 2 - diagnosis; Genes; Genetic Predisposition to Disease; Genotype & phenotype; Glucose Intolerance; Health risk assessment; Humans; Immunology; Insulin resistance; Islets of Langerhans; Latent Autoimmune Diabetes in Adults - diagnosis; Latent Autoimmune Diabetes in Adults - therapy; Metabolic syndrome; Pathogenesis; Peptides; China
• ISSN: 0366-6999; 2542-5641
• DOI: 10.1097/CM9.0000000000001321

[...]the 2020 international consensus on LADA highlighted that all these clinical characteristics help to identify LADA but could not categorically define LADA. According to the 1999 WHO and 2020 ADA recommendations for the classification of diabetes, LADA is classified as T1D,[6,7] but in the latest 2019 WHO classification of diabetes, LADA is referred to as “slowly evolving, immune-mediated diabetes of adults” and is classified as “hybrid forms of diabetes”. [...]LADA patients with high GADA titer resembles T1D more closely; alternatively, those with low GADA titer resembles T2D patients in metabolic presentation and beta cell function during follow-up. Insulin gene, protein tyrosine phosphatase non-receptor type 22 gene, and transcription factor 7-like 2 gene have also been reported as related to additional genetic risk for LADA, but their effects warrant further investigations across diverse ethnic groups with a larger sample size.